Skip to main content
TipRanks
Go Ultimate75% OFF

Molina Healthcare (MOH) AI Stock Analysis

1,208 Followers
MOH

Molina Healthcare

(NYSE:MOH)

Select Model
Rating:57Neutral
Price Target:$241.00â–²(8.95% Upside)
Action:reiterated
Date:11/17/26

MOH scores as mid-range: the largest drag is weakened financial performance (profitability compression, TTM net loss, and cash-flow volatility). Offsetting this are constructive technicals (price above key moving averages with positive momentum) and an encouraging earnings-call outlook with reaffirmed 2026 guidance and stronger 2027 earnings building blocks, though elevated medical cost trend and membership attrition remain notable risks. Valuation is also a headwind given the negative P/E and lack of dividend yield data.

Positive Factors
Government-sponsored recurring revenueMolina’s capitated government-program model provides recurring premium revenue tied to enrollment and contracted coverage. Its ability to manage utilization and medical costs against those premiums can support durable earnings, while state and federal contracts create a scalable operating platform.
Negative Factors
Profitability compressionThe shift from healthy prior-year profitability to a TTM net loss indicates materially weaker earnings resilience. Lower margins reduce internally generated capital for growth and leave results more exposed to medical utilization, pricing execution, and adverse changes in member acuity.

Molina Healthcare Key Performance Indicators (KPIs)

Total MembersTracks the total number of individuals enrolled in Molina Healthcare plans, indicating market reach and potential revenue base.

0.001.00M2.00M3.00M4.00M5.00M6.00MMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

Membership moves in sharp step‑changes (late‑2021 and early‑2024) rather than steady organic growth, suggesting wins/losses or policy shifts drive volumes. The abrupt drop through early‑mid 2026 wipes out much of the 2024–25 gains, implying a material contract loss or Medicaid redetermination impact that will meaningfully reduce revenue visibility and could pressure margins if the lost lives were lower‑cost. Treat membership as binary event risk — monitor state renewals, redetermination trends and management’s commentary on retention or replacement contracts for guidance on near‑term results.

Data provided by:The Fly

Molina Healthcare (MOH) vs. SPDR S&P 500 ETF (SPY)

-20%0%20%40%60%80%100%MOH+64.46%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$11.55B
Dividend Yield
―
Average Volume (3M)
779.97K
Price to Earnings (P/E)
-364.7
Beta (1Y)
-0.16
Revenue Growth
-0.95%
EPS Growth
-105.84%
Country
US
Employees
19,000
Sector
Healthcare
Sector Strength
51
Industry
Medical - Healthcare Plans

Molina Healthcare Business Overview & Revenue Model

Company Description

Molina Healthcare, Inc. offers comprehensive managed health care services, primarily targeting economically disadvantaged families and individuals. The company provides coverage through key government initiatives such as Medicaid and Medicare program...

How the Company Makes Money

Molina Healthcare makes money primarily by operating managed health plans under contracts with government agencies and, in some cases, through participation in government-sponsored insurance programs. Its core revenue model is based on premiums (ofte...

Molina Healthcare Earnings Call Summary

Earnings Call Date:Oct 21, 2026(Q3-2026)|% Change Since:2.94%|Next Earnings Date:Feb 10, 2027
Earnings Call SentimentPositive

The call was broadly optimistic. Third-quarter results were in line with expectations, 2026 guidance was reaffirmed, the balance sheet remained strong, and management highlighted improving Medicaid rate conditions, strong duals performance, the successful Florida CMS implementation, and preliminary 2027 earnings building blocks above $9.50 per share. The main challenges were elevated medical cost trend, membership declines, current-year MAPD and Marketplace losses, the initial Florida CMS loss, and delays to the Georgia and Texas contracts. Overall, the number and significance of the positive developments outweighed the stated challenges.

Positive Updates

Third-Quarter Results Met Expectations
Molina reported approximately $10.5 billion of premium revenue, adjusted EPS of $0.89, a 92.9% consolidated MCR, a 6.3% adjusted G&A ratio, and a 0.6% adjusted pre-tax margin for the third quarter. Year-to-date adjusted pre-tax margin was 1.1%.

Negative Updates

Elevated Medical Cost Trend
Management increased its full-year 2026 medical cost trend outlook from 5%-5.5% to 5.5% because of elevated utilization in several medical cost categories and a slight acuity shift. LTSS and behavioral health trends remained elevated, while outpatient services and high-cost drugs were slightly higher.

Company Guidance

For 2026, Molina reaffirmed premium revenue guidance of approximately $42 billion and adjusted earnings guidance of at least $5.25 per share, with consolidated MCR at 92.6%, adjusted G&A ratio at approximately 6.4%, Medicaid MCR at 92.9%, Medicare MCR at 92.2%, and Marketplace MCR at 90%; guidance now includes rates at 4.5% and trend at 5.5%, with implied fourth quarter adjusted EPS of $0.50, Medicaid MCR of 93.6% (92.5% excluding Florida CMS), Medicare MCR of 94.7%, and Marketplace MCR of 96.1%. For 2027, premium revenue is expected to be at least $45 billion, preliminary EPS building blocks sum to more than $9.50 per share, known embedded earnings remain approximately $9 per share, and $4 per share of embedded earnings is expected to be harvested, while Medicaid rates may approximate 6%, medical cost trend is projected in a range of 5.5%-6% including 50 basis points of conservatism, membership attrition is expected to be 6%, Marketplace is expected to reach at least breakeven, and every 100 basis points of Medicaid MCR is worth approximately $5 per share.

Molina Healthcare Financial Statement Overview

Summary

Financials look pressured and transitional. Profitability deteriorated sharply versus 2023–2024, with 2025 margin compression and TTM moving to a small net loss. Leverage is moderate but rising (debt roughly equal to equity), reducing flexibility. Cash flow has been volatile—negative in 2025, with a TTM recovery but lower free cash flow versus prior strength—keeping near-term execution risk elevated.

Income Statement

44Neutral

Balance Sheet

63Positive

Cash Flow

39Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue43.63B45.43B40.65B34.07B31.97B27.77B
Gross Profit3.52B4.08B4.74B4.33B3.93B3.28B
EBITDA333.00M976.00M1.89B1.74B1.35B1.13B
Net Income-48.00M472.00M1.18B1.09B792.00M659.00M
Balance Sheet
Total Assets15.65B15.56B15.63B14.89B12.31B12.21B
Cash, Cash Equivalents and Short-Term Investments8.58B8.26B8.99B9.11B7.50B7.64B
Total Debt3.95B3.95B3.12B2.38B2.39B2.39B
Total Liabilities11.50B11.49B11.13B10.68B9.35B9.58B
Stockholders Equity4.16B4.07B4.50B4.21B2.96B2.63B
Cash Flow
Free Cash Flow238.00M-636.00M544.00M1.58B682.00M2.04B
Operating Cash Flow331.00M-535.00M644.00M1.66B773.00M2.12B
Investing Cash Flow-98.00M312.00M-464.00M-744.00M-790.00M-1.65B
Financing Cash Flow61.00M-170.00M-347.00M-58.00M-441.00M-183.00M

Molina Healthcare Technical Analysis

Technical Analysis SentimentPositive
Last Price221.21

Price Trends

50DMA203.72Positive
100DMA206.93Positive
200DMA186.26Positive

Market Momentum

MACD4.04Negative
RSI57.20Neutral
STOCH61.10Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MOH, the sentiment is Positive. The current price of 221.21 is above the 20-day moving average (MA) of 210.39, above the 50-day MA of 203.72, and above the 200-day MA of 186.26, indicating a bullish trend. The MACD of 4.04 indicates Negative momentum. The RSI at 57.20 is Neutral, neither overbought nor oversold. The STOCH value of 61.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MOH.

Molina Healthcare Risk Analysis

Molina Healthcare disclosed 41 risk factors in its most recent earnings report. Molina Healthcare reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

3 New Risks
1.The Medicaid rates paid to us by states may be insufficient to cover our rising medical care costs.Q4, 2025
2.Restrictive covenants in our debt instruments may restrict our ability to pursue our business strategies.Q4, 2024
3.Changes in tax laws or regulations that are applied adversely to us or our customers may materially adversely affect our business, prospects, financial condition and operating results.Q4, 2024

Molina Healthcare Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

MOH against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
ELVELV76Outperform$93.75B18.4511.59%1.58%3.60%-4.06%
CICI75Outperform$77.49B12.9214.10%2.11%6.79%-0.38%
CNCCNC66Neutral$35.92B24.466.78%―9.71%―
UNHUNH62Neutral$349.16B22.1416.35%2.33%3.33%-8.75%
HUMHUM58Neutral$53.25B42.486.70%0.80%22.02%-3.07%
MOHMOH57Neutral$11.55B-364.70-1.17%―-0.95%-105.84%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

0%50%100%MOHCNCCIHUMUNHELVDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
MOH and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
MOHMolina Healthcare Inc221.2183.0960.16%
CNCCentene72.5536.60101.81%
CICigna294.0628.1010.56%
HUMHumana443.34217.3996.21%
UNHUnitedhealth Group Inc.389.6888.6129.43%
ELVElevance Health, Inc.433.93123.7339.89%

Molina Healthcare Corporate Events

Other

Molina Healthcare Management to Participate in UBS Healthcare Conference

Neutral
Nov 6, 2026

Molina Healthcare announced that members of its senior management team were scheduled to participate in UBS’s Global Healthcare Conference on November 9, 2026. The planned investor discussions were to cover the company’s business and financial result...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 17, 2026